obesity and overweight - All mecanism - all type of patients clinical trials results meta-analysis

<h1> <a href="index.html"> <strong>obesity and overweight</strong> - All mecanism </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="index.html"> Anderson, 2002 </a> <br> </td> <td> Bupropion, variabledose for 48 wk<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up <br> n=105/112<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Croft, 2002 </a> <br> </td> <td> Bupropion, 300 mgfor 44 wk<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up <br> n=210/213<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Jain, 2002 </a> <br> </td> <td> Bupropion, variabledose for 24 wk<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up <br> n=213/209<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Breum, 1995 </a> <br> </td> <td> Fluoxetine, 60 mgfor 52 wk<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up <br> n=20/20<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Connolly, 1995 </a> <br> </td> <td> Fluoxetine, 60 mgfor 6 mo<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up <br> n=15/15<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Darga, 1991 </a> <br> </td> <td> Fluoxetine, 60 mgfor 52 wk<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up <br> n=23/22<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Goldstein, 1994 </a> <br> </td> <td> Fluoxetine, 60 mgfor 52 wk<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up <br> n=182/184<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Gray, 1992 </a> <br> </td> <td> Fluoxetine, 60 mgfor 6 mo<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up <br> n=24/24<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Marcus, 1990 </a> <br> </td> <td> Fluoxetine, 60 mgfor 52 wk<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up <br> n=23/22<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Mendoza Espejo, 1995 </a> <br> </td> <td> Fluoxetine, 180 mgfor 6 mo<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up <br> n=0/30<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Michelson 50wk, 1999 </a> <br> </td> <td> Fluoxetine, 20 mgfor 50 wk<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up <br> n=102/102<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> O�Kane, 1994 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=10/10<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Bakris, 2002 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=278/276<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Broom, 2002 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=265/261<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Broom,, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=71/71<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Davidson, 1999 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=668/224<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Deerochanawong,, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=126/126<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Derosa, 2003 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=27/23<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Gotfredsen, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=16/14<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Halpern, 2003 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=169/174<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hanefeld, 2002 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=195/188<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hauptman, 2000 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=210/212<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hill, 1999 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=181/188<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hollander, 1998 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=163/159<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Karhunen, 2000 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=36/36<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Kelley, 2002 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=274/276<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Krempf, 2005 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=346/350<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Lindgarde, 2000 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=190/186<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Lucas, 2003 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=256/188<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Micic, 1999 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=60/59<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Miles, 2002 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=255/261<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Muls, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=147/147<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Naumov, 2002 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=15/15<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Reaven, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=156/91<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Rissanen, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=25/26<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Rosenfalck, 2002 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=3/1<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Rossner, 2000 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=244/243<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Shi Yi, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=986/142<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Sjostrom, 1998 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=345/343<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Vidgren, 1999 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=37/38<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Bray, 2003 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=75/75<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Caterson, 2003 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=93/97<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Pud�homme, 2003 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=33/33<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Rissanen, 2003 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=123/103<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Stenlof, 2003 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=135/137<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Tonstad, 2003 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=178/177<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> McMahon , 2000 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=142/157<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> McMahon, 2002 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=145/72<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Smith, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=142/69<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Astrup, 0 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Astrup (NN8022-1807 ), 2009 </a> <br> NCT00422058 </td> <td> 4 liraglutide doses (1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg daily)<br>  <i>versus</i> <br> placebo </td> <td> obese individuals without type 2 diabetes </td> <td> follow-up 20 weeks<br> n=-9/-9<br> Parallel groups<br> double blind <br> Europe </td> </tr> <tr> <td> <a href="index.html"> BLOSSOM, 2009 </a> <br> </td> <td> lorcaserin 10 mg twice daily<br>  <i>versus</i> <br> placebo </td> <td> obese and overweight patients </td> <td> follow-up 1 year<br> n=-9/-9<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> SCOUT, </a> <br> </td> <td> sibutramine<br>  <i>versus</i> <br> placebo </td> <td> overweight or obese patients with diabetes or a history of coronary or peripheral vascular disease or stroke, along with other CV risk factors </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> double blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>Anderson, 2002 : </b> Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PMBupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. <i>Obes Res 2002 Jul;10:633-41</i> [PMID 12105285] </p> <p> <b>Croft, 2002 : </b> Croft H, Houser TL, Jamerson BD, Leadbetter R, Bolden-Watson C, Donahue R, Metz AEffect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. <i>Clin Ther 2002 Apr;24:662-72</i> [PMID 12017410] </p> <p> <b>Jain, 2002 : </b> Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz ABupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. <i>Obes Res 2002 Oct;10:1049-56</i> [PMID 12376586] </p> <p> <b>Breum, 1995 : </b> Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup ALong-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. <i>Metabolism 1995 Dec;44:1570-6</i> [PMID 8786726] </p> <p> <b>Connolly, 1995 : </b> Connolly VM, Gallagher A, Kesson CMA study of fluoxetine in obese elderly patients with type 2 diabetes. <i>Diabet Med 1995 May;12:416-8</i> [PMID 7648804] </p> <p> <b>Darga, 1991 : </b> Darga LL, Carroll-Michals L, Botsford SJ, Lucas CPFluoxetine's effect on weight loss in obese subjects. <i>Am J Clin Nutr 1991 Aug;54:321-5</i> [PMID 1858696] </p> <p> <b>Goldstein, 1994 : </b> Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LRFluoxetine: a randomized clinical trial in the treatment of obesity. <i>Int J Obes Relat Metab Disord 1994 Mar;18:129-35</i> [PMID 8186809] </p> <p> <b>Gray, 1992 : </b> Gray DS, Fujioka K, Devine W, Bray GAFluoxetine treatment of the obese diabetic. <i>Int J Obes Relat Metab Disord 1992 Mar;16:193-8</i> [PMID 1317828] </p> <p> <b>Marcus, 1990 : </b> Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding WA double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. <i>Am J Psychiatry 1990 Jul;147:876-81</i> [PMID 2192563] </p> <p> <b>Mendoza Espejo, 1995 : </b> Mendoza Espejo R, Diaz Perez de Madrid J, Buitrago F[Effectiveness of serotonergic agonists in the treatment of obese patients] <i>Aten Primaria 1995 Oct 15;16:364-6</i> [PMID 7488690] </p> <p> <b>Michelson 50wk, 1999 : </b> Michelson D, Amsterdam JD, Kim Y, Sundell K.ntenChanges in weight during a one-year trial with fluoxetine [Abstract] <i>152nd Annual Meeting of</i> [PMID ] </p> <p> <b>O�Kane, 1994 : </b> O'Kane M, Wiles PG, Wales JKFluoxetine in the treatment of obese type 2 diabetic patients. <i>Diabet Med 1994 Jan-Feb;11:105-10</i> [PMID 8181239] </p> <p> <b>Bakris, 2002 : </b> Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma IOrlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. <i>J Hypertens 2002 Nov;20:2257-67</i> [PMID 12409965] </p> <p> <b>Broom, 2002 : </b> Broom I, Wilding J, Stott P, Myers NRandomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. <i>Int J Clin Pract 2002 Sep;56:494-9</i> [PMID 12296610] </p> <p> <b>Broom,, 2001 : </b> Broom I.Randomised trial of the effect of orlistat on body weight and CVD risk profile in overweight and obese patients with co-morbidities [Abstract]. <i>Int J Obes. 2001;25 Suppl:S106</i> [PMID ] </p> <p> <b>Davidson, 1999 : </b> Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SBWeight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. <i>JAMA 1999 Jan 20;281:235-42</i> [PMID 9918478] </p> <p> <b>Deerochanawong,, 2001 : </b> Deerochanawong C.Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes [Abstract]. <i>Diabetes. 2001;50:A433.</i> [PMID ] </p> <p> <b>Derosa, 2003 : </b> Derosa G, Mugellini A, Ciccarelli L, Fogari RRandomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. <i>Clin Ther 2003 Apr;25:1107-22</i> [PMID 12809960] </p> <p> <b>Gotfredsen, 2001 : </b> Reaven G, Segal K, Hauptman J, Boldrin M, Lucas CEffect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. <i>Am J Cardiol 2001 Apr 1;87:827-31</i> [PMID 11274935] </p> <p> <b>Halpern, 2003 : </b> Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AGLatin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. <i>Diabetes Obes Metab 2003 May;5:180-8</i> [PMID 12681025] </p> <p> <b>Hanefeld, 2002 : </b> Hanefeld M, Sachse GThe effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. <i>Diabetes Obes Metab 2002 Nov;4:415-23</i> [PMID 12406041] </p> <p> <b>Hauptman, 2000 : </b> Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KROrlistat in the long-term treatment of obesity in primary care settings. <i>Arch Fam Med 2000 Feb;9:160-7</i> [PMID 10693734] </p> <p> <b>Hill, 1999 : </b> Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJOrlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. <i>Am J Clin Nutr 1999 Jun;69:1108-16</i> [PMID 10357727] </p> <p> <b>Hollander, 1998 : </b> Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman JRole of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. <i>Diabetes Care 1998 Aug;21:1288-94</i> [PMID 9702435] </p> <p> <b>Karhunen, 2000 : </b> Karhunen L, Franssila-Kallunki A, Rissanen P, Valve R, Kolehmainen M, Rissanen A, Uusitupa MEffect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. <i>Int J Obes Relat Metab Disord 2000 Dec;24:1567-72</i> [PMID 11126207] </p> <p> <b>Kelley, 2002 : </b> Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander PClinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. <i>Diabetes Care 2002 Jun;25:1033-41</i> [PMID 12032111] </p> <p> <b>Krempf, 2005 : </b> Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JRWeight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. <i>Int J Obes Relat Metab Disord 2003 May;27:591-7</i> [PMID 12704403] </p> <p> <b>Lindgarde, 2000 : </b> Lindgarde FThe effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. <i>J Intern Med 2000 Sep;248:245-54</i> [PMID 10971792] </p> <p> <b>Lucas, 2003 : </b> Lucas CP, Boldrin MN, Reaven GMEffect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. <i>Am J Cardiol 2003 Apr 15;91:961-4</i> [PMID 12686336] </p> <p> <b>Micic, 1999 : </b> Micic D, Ivkovic-Lazar T, Dragojevic R, Jorga J, Stokic E, Hajdukovic ZOrlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. <i>Med Pregl 1999 Sep-Oct;52:323-33</i> [PMID 10624380] </p> <p> <b>Miles, 2002 : </b> Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, Foreyt J, Aronne L, Klein SEffect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. <i>Diabetes Care 2002 Jul;25:1123-8</i> [PMID 12087008] </p> <p> <b>Muls, 2001 : </b> Muls E, Kolanowski J, Scheen A, Van Gaal LThe effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. <i>Int J Obes Relat Metab Disord 2001 Nov;25:1713-21</i> [PMID 11753595] </p> <p> <b>Naumov, 2002 : </b> Naumov VG, Lupanov VP, Dotsenko IuV, Tvorogova MG[Six-month xenical (orlistat) therapy of patients with stable angina pectoris concomitant with obesity and hyperlipidemia] <i>Ter Arkh 2002;74:47-51</i> [PMID 11878059] </p> <p> <b>Reaven, 2001 : </b> Reaven G, Segal K, Hauptman J, Boldrin M, Lucas CEffect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. <i>Am J Cardiol 2001 Apr 1;87:827-31</i> [PMID 11274935] </p> <p> <b>Rissanen, 2001 : </b> Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen AWeight change and blood coagulability and fibrinolysis in healthy obese women. <i>Int J Obes Relat Metab Disord 2001 Feb;25:212-8</i> [PMID 11410822] </p> <p> <b>Rosenfalck, 2002 : </b> Rosenfalck AM, Hendel H, Rasmussen MH, Almdal T, Anderson T, Hilsted J, Madsbad SMinor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. <i>Diabetes Obes Metab 2002 Jan;4:19-28</i> [PMID 11890163] </p> <p> <b>Rossner, 2000 : </b> Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda GWeight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. <i>Obes Res 2000 Jan;8:49-61</i> [PMID 10678259] </p> <p> <b>Shi Yi, 2001 : </b> Shi Yi F, Zhu Jun R.Effect of orlistat on weight loss and glycemic control in overweight Chinese patients with type 2 diabetes [Abstract]. <i>Diabetes. 2001;50:A101-A102</i> [PMID ] </p> <p> <b>Sjostrom, 1998 : </b> Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf MRandomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. <i>Lancet 1998 Jul 18;352:167-72</i> [PMID 9683204] </p> <p> <b>Vidgren, 1999 : </b> Vidgren HM, Agren JJ, Valve RS, Karhunen LJ, Rissanen AM, Uusitupa MIThe effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. <i>Clin Pharmacol Ther 1999 Sep;66:315-22</i> [PMID 10511068] </p> <p> <b>Bray, 2003 : </b> Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BHA 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. <i>Obes Res 2003 Jun;11:722-33</i> [PMID 12805393] </p> <p> <b>Caterson, 2003 : </b> Caterson I, Astrup A, Zelissen P, Guy-Grand B, Carruba M, Levy B, et al.The long-term effect of topiramate on body weight maintenance after low-calorie diet-induced weight loss in obese subjects [Abstract]. <i>Presented at the 18th International Diabetes Federation Congress, Paris, France, 24�29 August 2003.</i> [PMID ] </p> <p> <b>McMahon , 2000 : </b> McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian ADEfficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. <i>Arch Intern Med 2000 Jul 24;160:2185-91</i> [PMID 10904462] </p> <p> <b>McMahon, 2002 : </b> McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka KSibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. <i>J Hum Hypertens 2002 Jan;16:5-11</i> [PMID 11840224] </p> <p> <b>Smith, 2001 : </b> Smith IG, Goulder MARandomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. <i>J Fam Pract 2001 Jun;50:505-12</i> [PMID 11407998] </p> <p> <b>Astrup, 0 : </b> Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TMEffect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. <i>Lancet 2008;372:1906-13</i> [PMID 18950853] </p> <p> <b>Astrup (NN8022-1807 ), 2009 : </b> Astrup A, R�ssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean MEEffects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. <i>Lancet 2009 Oct 22;:</i> [PMID 19853906] 10.1016/S0140-6736(09)61375-1 </p> <p> <b>BLOSSOM, 2009 : </b> Kaplan LM, Smith SR, Weissman NJ, et alThe BLOSSOM trial: efficacy and safety of lorcaserin in obese and overweight men and women <i>Obesity 2009; October 27, 2009; Washington, DC</i> [PMID ] </p> <p> <b>SCOUT, : </b> James W. P. T.The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients <i>Eur Heart J Suppl 2005;7:L44-48</i> [PMID ] </p> <p> <b>SCOUT, : </b> Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James PCardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. <i>Eur Heart J 2007 Dec;28:2915-23</i> [PMID 17595194] </p>